🔬At a glance
800+ clinical professionals
200+ international clients
Global presence across China, the U.S., Australia
🔬Core expertise
Phase I–III clinical trial execution
IITs as a complementary and flexible development strategy
Full clinical services: Regulatory, Medical, Clinical Ops, DM, Statistics, PV
Strong experience in oncology, autoimmune, CNS, ophthalmology, metabolic & infectious diseases, including cell & gene therapies (ex vivo & in vivo CAR-T)
🌐Why China. Why PanaCRO.
China offers unique advantages in patient access, enrollment speed, and site maturity—and PanaCRO brings the local execution strength and global-standard rigor needed to run complex trials with confidence.
With trusted partners like PanaCRO joining the BCIC ecosystem, we continue to expand not only clinical development capabilities for innovators but also the capital, visibility, and strategic resources that help early-stage biotech companies scale globally.
🎉If you’re building the next breakthrough therapy, this is exactly the type of ecosystem designed to support you.
The 2026 Biomedical Pitch Competition has been open for registration.
Don’t miss your chance to gain the visibility and support needed to scale your breakthrough.
Register now:(https://lnkd.in/ePTt9247)
Also our upcoming webinar: Unlocking Pre-IPO Investing: Democratizing Access to High-Growth Private Equity
Date: February 12, 2026 (Thursday)
Time: 7:00 PM – 8:15 PM EST
Format: Virtual Only (Zoom Webinar)
Register Here: (https://lnkd.in/eiemMvQt)
Don’t miss this opportunity to explore the next paradigm of private equity investment!
A trusted China clinical development partner joins the Boston Capital Investment Club ecosystem! 🎉
We’re excited to introduce PanaCRO, a full-service clinical CRO and long-term clinical development partner in China.
#Biotech #Startups #CRO #VentureCapital #Biomedical #PitchCompetition #BCIC